Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is an anticonvulsant presented as an intravenous solution for intravenous use. It treats partial‑onset seizures and is used as adjunctive therapy in epilepsy.

GNH USA supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant indicated for specific seizure types and epilepsy management.

Partial‑onset seizures: Reduces seizure frequency when added to existing antiepileptic regimens. Adjunctive therapy for epilepsy: Provides additional seizure control in patients not fully controlled by other medications. Generalized epilepsy: May be incorporated into combination therapy to improve overall seizure management.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue - Blurred vision - Somnolence

Serious or Rare Side Effects: - Cardiac arrhythmia (e.g., PR‑interval prolongation) - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior - Respiratory depression - Anaphylactic reactions - Elevated liver enzymes

When prescribing Lacosamide, consider the following safety measures.

Renal impairment: Adjust monitoring and consider dose modification. Hepatic impairment: Use with caution and monitor liver function. Cardiac conduction disorders: Perform baseline ECG and monitor for PR‑interval changes. Concomitant CNS depressants: Assess additive sedation risk. Pregnancy: Potential risk unknown; discuss benefits and risks with the patient. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze.

Lacosamide can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Class I antiarrhythmics: May increase risk of cardiac arrhythmias. - Carbamazepine: Can reduce lacosamide plasma concentrations. - Strong CYP2C19 inhibitors (e.g., fluconazole): May raise lacosamide exposure.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., valproate): Monitor seizure control efficacy. - Alcohol: May enhance central nervous system depression. - Warfarin: Monitor INR for potential anticoagulant effect changes.